HEALTHXHealth X Platform Limited
Pharma · Pharmaceutical Retailers · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Health X Platform Limited operates a digital network of healthcare and portfolio management services in India. The company operates through the Financial Services and Healthcare Network segments. It is involved in the financing of loans; investment in shares and securities; and activities for pathology and marketing of healthcare and OTC products through e-commerce portal. The company also provides financial consultancy, professional fees, wealth management, financial planning, distribution, and related services, as well as diagnostic services, including pathological/radiological investigation. In addition, it operates digital platforms for healthcare, including the Sastasundar app, a consumer-focused digital healthcare platform consisting of pharmacy, diagnostics, and wellness; and retailershakti.com, a B2B digital platform for pharmaceutical and wellness products. The company was formerly known as Sastasundar Ventures Limited Limited and changed its name to Health X Platform Limited in February 2026. Health X Platform Limited was incorporated in 1989 and is based in Kolkata, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 42.0% YoY
- • Debt/Equity: 0.03
- • Promoter holding: 79.9%
- • RSI: 56
- • MACD: bullish
- • Price vs EMA21: above
- • EMA Crossover signal (setup quality 62%)
- • Pullback to 21-EMA signal (setup quality 66%)
Bull case
- • Revenue growth: 42.0% YoY
- • Debt/Equity: 0.03
- • Promoter holding: 79.9%
- • RSI: 56
Bear case
- • Profit growth: -89.4% YoY
- • ROE: 0.2%
- • Supertrend: bearish
- • Volume: 0.7x 20-day average
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -89.4% YoY
- • ROE: 0.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹13.67). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.